DMD # 737 4 The 3'-ethynyl nucleosides, 1-(3-C-ethynyl-ß-D-ribo-pentofuranosyl)cytosine (ECyd) and 1-(3-C-ethynyl-ß-D-ribo-pentofuranosyl)uracil (EUrd), are antitumor ribo-nucleoside analogues of cytidine and uridine, respectively. We previously reported that both ECyd and EUrd exhibit significant cytotoxicity and antitumor activity on various types of animal and human solid tumors in in vivo models (Hattori et al., 1996; Tanaka et al., 1997; Takatori et al., 1999) . ECyd, which is currently undergoing a phase I study, is a unique anticancer drug possessing a potent inhibitory effect on RNA polymerases. Both ECyd and EUrd incorporated into cells are rapidly phosphorylated to a mono-phosphate form by uridine/cytidine kinase (UCK, EC 2.7.1.48) and these mono-phosphates are subsequently phosphorylated to the corresponding di-(ECDP and EUDP) and tri-phosphates (ECTP and EUTP) (Shimamoto et al., 2002a) . The tri-phosphates are active metabolites and inhibit RNA synthesis by blocking RNA polymerases I, II, and III (Tabata et al., 1997; Matsuda et al., 1999; Takatori et al., 1999) .
Intracellular accumulation of the tri-phosphates is therefore considered to be critical for the 3'-ethynyl nucleosides to exert a cytotoxic activity. We have reported that the sensitivity of tumor cells to EUrd is well-correlated with the inhibition of cellular RNA synthesis by EUrd and that the inhibition of cellular RNA synthesis by EUrd is also associated with intracellular accumulation of EUTP (Hattori et al., 1996) .
We previously reported that EUrd-resistant human fibrosarcoma HT-1080 cells possessed diminished UCK activity. However, the mechanism of the enzymatic deficiency of UCK has not yet been clarified. We have also demonstrated that the decrease of deoxycytidine kinase activity leads tumor cells to acquire resistance to antitumor 2'-deoxycytidine analogues including Ara-C and gemcitabine and the enzymatic deficiency is frequently caused by mutation of the deoxycytidine kinase gene (Obata et al., 2001) . Therefore, the EUrd-resistant HT-1080 may harbor a mutation in the UCK gene. More recently, the UCK family which This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on July 27, 2004 as DOI: 10.1124 at ASPET Journals on August 27, 2017 dmd.aspetjournals.org Downloaded from DMD # 737 5 consists of at least two members, UCK1 and UCK2, has been found to be present in human cells (Van Rompay et al., 2001) . The UCK1 gene encodes a 277-amino acid protein with a predicted molecular mass of 31 kDa. The UCK2 gene encodes a 261-amino acid protein (29 kDa). UCK1 and UCK2 share 68.8% identity at the deduced amino acid level. Although many tumors express both UCK1 and UCK2, their role in the phosphorylation of 3'-ethynyl nucleosides is not fully understood. To elucidate the resistance mechanisms of 3'-ethynyl nucleosides and the distinct roles of UCK1 and UCK2 in production of 3'-ethynyl nucleoside monophosphates, we investigated the expression of UCKs and underlying genetic mutations in resistant cells. We subsequently found that UCK2 mRNA expressed in the EUrd-resistant HT-1080 and human gastric cancer NUGC-3 cells harbored nonsense and missense mutations, respectively. In the present study, we demonstrate that UCK2 plays an exclusive role in the intracellular phosphorylation of 3'-ethynyl nucleosides and is a molecular target for acquired resistance to the nucleosides. This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Chemicals. EUrd and ECyd were chemically synthesized as previously reported (Hattori et al., 1996) . Ara-C was kindly provided from YAMASA Co., Choshi, Japan.
Establishment of resistant tumor cells.
Human fibrosarcoma HT-1080 cells were obtained from the American Type Culture Collection (Rockville, MD), and human stomach carcinoma NUGC-3 cells were obtained from Japanese Collection of Research Bioresources (National Institute of Health Sciences, Cell Bank, Tokyo, Japan). The cells were maintained as a monolayer culture in RPMI 1640 medium (Nissui pharmaceutical, Osaka, Japan) containing 10% heat-inactivated fetal bovine serum (GIBCO, Grand Island, NY) and kanamycin (50 µg/ml). The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO 2 .
EUrd-resistant and ECyd-resistant variants of HT-1080 (HT-1080/EUrd and HT-1080/ECyd) and NUGC-3 (NUGC-3/EUrd and NUGC-3/ECyd) were developed by continuous exposure of cells to EUrd or ECyd, starting with a concentration of 0.1 ng/ml (Tabata et al., 1997) . When the cells grew logarithmically at the maximum growth rate, the concentration was increased incrementally. Finally, the cells could proliferate logarithmically in culture medium containing EUrd (10 µg/ml) and ECyd (10 µg/ml).
Cytotoxicity assay. In vitro cytotoxicity was examined using a modified tetrazolium-based semi-automatic colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma, St. Louis, MO) as reported previously (Carmichael et al., 1987; Tanaka et al., 1992) . Briefly, 180 µl aliquots of an exponentially growing cell suspension (0.5-2 x 10 3 cells) were incubated in a 96-well microplate for 24 h, then 20 µl of drugs were added at various concentrations. After exposure for 72 h, 25 µl of 2 mg/ml MTT was added to each well, and the cell cultures were incubated at 37°C for 4 h. The medium was This article has not been copyedited and formatted. The final version may differ from this version. carefully removed and 200 µl of DMSO was added to each well to dissolve the formed formazan. After thorough mixing, the absorbance of each well was measured at 540 nm using a Model immuno-mini NJ-2300 (Nihon Intermed, Tokyo, Japan). Each experiment was performed using triplicate wells for each drug concentration and two or three independent experiments were carried out to confirm the reproducibility. The percentage of relative cell survival was calculated by applying the following formula: % of relative cell survival = T / C x 100, where C is the mean A 540 of the control group and T is that of the treated group. The 50% inhibitory drug concentration (IC 50 value) was measured graphically from the dose-response curve with at least three drug concentration points.
RT-PCR analysis of UCK mRNA expression.
The RT-PCR analysis was conducted by a modification of the method of Conboy et al (Conboy et al., 1988) . Briefly, total RNA was extracted using ISOGEN (Nippon Gene, Tokyo, Japan) (Chomczynski and Sacchi, 1987) . The prepared RNA was mixed with oligo(dT), incubated for 10 min at 68°C and then quickly for three cycles, followed by 27 cycles of 40 s at 94°C, 1.5 min at 48°C and 1.3 min at 72°C on a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT). The PCR products were electrophoresed on a 1% agarose gel. Specific primers are presented in Table 1 .
Cycle sequencing. The PCR products of the UCK1 and UCK2 cDNA including a full-length coding region were purified using a QIAEX II Gel Extraction Kit (QIAGEN, Hilden, Germany). The purified PCR fragments were sequenced by a cycle-sequencing method using Gene Rapid (Amersham Pharmacia Biotech, Uppsala, Sweden) and a Thermo Sequenase Cy5.5 Terminator Cycle Sequencing Kit (Amersham Pharmacia Biotech).
Western blot analysis for UCK1 and UCK2 proteins. Protein was extracted from
HT-1080/EUrd and NUGC-3/EUrd cells with RIPA buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS]. After centrifugation for 10 min at 15,000 rpm at 4°C, the lysate supernatant was assayed for protein concentration using a BCA protein assay kit (Pierce, Rockford, Ill). Samples were electrophoresed on a SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Millipore Corporation, Bedfold, MA) by electroblotting. Non-specific binding was blocked by incubation with 5% non-fat dry milk in TBS-T [20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.05% Tween 20] overnight at 4°C. The membrane was washed with TBS-T, then incubated with anti-UCK1 or anti-UCK2 rabbit polyclonal antibody (a gift from Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) (Shimamoto et al., 2002b) for 1 h at room temperature. After further washing with TBS-T and subsequent incubation with horseradish peroxidase-conjugated anti-rabbit IgG, specific complexes were detected by the ECL chemiluminescence technique (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
Creation of recombinant UCK2 from NUGC-3/EUrd cells. For recombinant protein
production and purification, the mutant UCK2 (R162W) gene was amplified by PCR from This article has not been copyedited and formatted. The final version may differ from this version. Finally, the mutant UCK2 gene of the resulting plasmid pPRO/UCK2 (R162W) was sequenced to confirm the entire nucleotide sequence. The expression plasmid pPRO/UCK2 (R162W) was transformed into the E.coli BL21 and was induced by adding IPTG.
Recombinant UCK2 (R162W) was purified by Ni-NTA column.
The uridine phosphorylation catalytic activity assay. Uridine phosphorylation activity of wild-type and mutant recombinant UCK2 were measured using uridine as a substrate according to the method of Shimamoto et al (Shimamoto et al., 2002b) . The significance of differences between wild-type and mutant recombinant UCK2 was determined by the Student's t test. A P value lower than 0.05 was considered to be significant. 
Results
Sensitivity to antitumor cytosine nucleosides. Table 2 presents HT-1080/EUrd cells produced an unexpected PCR product of UCK2 cDNA with a shorter size than an expected size (873 bp), but the intensity of the band was almost same as that from the parental HT-1080. In NUGC-3/EUrd cells, the expected fragment was observed, but the expression level of UCK2 was significantly decreased as compared with that of the parental NUGC-3 cells (Fig. 1) . In contrast, the expression of UCK1 mRNA did not change in all the parental and resistant cells.
Protein expression of UCK1 and UCK2 in resistant cells. The expression of UCK1 and
UCK2 proteins was examined by western blot using specific polyclonal antibodies (Shimamoto et al., 2002b) . The results showed that the expression level of UCK2 in HT-1080/EUrd and NUGC-3/EUrd was markedly decreased, but no change in UCK1 protein expression was shown between parental and resistant cells (Fig. 2) . substitution (C to T) at nucleotide position 484 within the fourth exon was observed (Fig. 4A ).
Mutations in EUrd
This mutation resulted in an amino-acid change from Arg to Trp. This point mutation could be found in genomic DNA from EUrd-resistant NUGC-3 cells (Fig. 4B ). NUGC-3/ECyd did not express UCK2 mRNA or protein, but had no mutation in the coding region of UCK2 cDNA (data not shown).
Uridine phosphorylation activity of recombinant UCK2 in NUGC-3/EUrd cells. To
investigate whether recombinant UCK2 expressed in NUGC-3/EUrd cells possesses uridine phosphorylation activity, we purified the recombinant mutant UCK2 (R162W) from E.coli.
The results showed that UCK2 from NUGC-3/EUrd cells has no enzymatic activity (Fig. 5 ).
Cytotoxicity of ECyd on HT-1080/EUrd cells. To examine whether sensitivity of
HT-1080/EUrd cells to ECyd is restored by forced expression of normal UCK2, we transfected UCK2 cDNA into HT-1080/EUrd. After transfection and G418-selection, growing clones were examined by western blotting to confirm UCK2 protein expression.
HT-1080/EUrd cells transfected with UCK2 cDNA overexpressed V5-His-tagged UCK2 polypeptide (34KDa). ECyd-sensitivity of HT-1080/EUrd overexpressing normal UCK2 was restored to the level of that in parental cells (Fig. 6 ). This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The first phosphorylation of the 3'-ethynyl nucleosides, EUrd and ECyd, is catalyzed by UCK and this step is thought to be rate-limiting. The level of cellular UCK activity therefore affects sensitivity to these 3'-ethynyl nucleosides. We have previously demonstrated that UCK activity was decreased concomitant with the progression of drug resistance to the 3'-ethynyl nucleosides (Tabata et al., 1997; Shimamoto et al., 2002a) . However, it was not clear which isozyme of UCKs is responsible for the phosphorylation of 3'-ethynyl nucleosides. We have established human tumor cell lines highly resistant to EUrd and ECyd.
These resistant cells showed a cross-resistance to both the 3'-ethynyl nucleosides. The results suggest that the resistant cell lines may harbor a mutation in UCK1 or UCK2. Eventually, we found a 98-bp deletion mutation in UCK2 mRNA from HT-1080/EUrd. Since the deletion site corresponded to exon 5 only, this mutation may result from a splicing disorder. However, we could not confirm a genomic DNA mutation upstream of exon 5 in the UCK2 gene by direct sequence analysis. We also analyzed the ±300 bp region of exons 4 and 6, but again no mutation was shown. In the sequence analysis we performed, the primer pairs used targeted a short region between 5'-and 3'-flanking introns of each exon (exons 4, 5, or 6) . Therefore, only the normal allele might be amplified if another allelic UCK2 gene has a gross deletion including exon 5 outside the annealing site of the primers used. Alternatively, the allelic 
cells. The expression level of UCK2 protein in EUrd-resistant cells was markedly decreased
as compared with that in parental cells, but no marked decrease of UCK1 protein was shown in EUrd-resistant cells. These mutant UCK2 proteins may have a short half-life due to their instability in cells. We examined the enzymatic activity of recombinant UCK2-R162W from NUGC-3/EUrd cells. The mutant UCK2 lacked Urd/Cyd kinase activity. We recently produced recombinant human UCK1 and UCK2 to investigate the kinetic parameters of UCK1 and UCK2 for the 3'-ethynyl nucleosides. Consequently, recombinant human UCK2 showed lower K m and higher V max values for the 3'-ethynyl nucleosides than UCK1 [K m (µM) and V max (nmol/mg/min) for ECyd: UCK1, 889 and 0.215; UCK2, 418 and 227]. The substrate efficiency (V max/ K m ) of UCK2 to ECyd was about 2,000 times higher than that of UCK1 (data not shown). Thus, these 3'-ethynyl nucleosides might be preferentially phosphorylated by UCK2.
In this study, we demonstrate that UCK2 is an exclusive target for the acquisition of resistance to the antitumor 3'-ethynyl nucleosides, EUrd and ECyd. Although UCK2 is expressed in many types of tissues and tumor cells, the expression level of UCK2 appears to be very diverse in cells. Recently the existence of single nucleotide polymorphisms in the UCK2 gene was reported (Hasegawa et al., 2002) . UCK2 may be a useful marker to predict chemosensitivity to antitumor uridine and cytidine analogues including EUrd and ECyd. In addition, UCK2 may be a novel molecular target for biochemical modulation to potentiate antitumor effects of such nucleoside analogues. This article has not been copyedited and formatted. The final version may differ from this version. 
